JP5952410B2 - 油中水型エマルション及びその調製方法 - Google Patents
油中水型エマルション及びその調製方法 Download PDFInfo
- Publication number
- JP5952410B2 JP5952410B2 JP2014532439A JP2014532439A JP5952410B2 JP 5952410 B2 JP5952410 B2 JP 5952410B2 JP 2014532439 A JP2014532439 A JP 2014532439A JP 2014532439 A JP2014532439 A JP 2014532439A JP 5952410 B2 JP5952410 B2 JP 5952410B2
- Authority
- JP
- Japan
- Prior art keywords
- phase
- emulsion
- oil
- water
- hydrophilic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007762 w/o emulsion Substances 0.000 title claims description 46
- 238000002360 preparation method Methods 0.000 title claims description 27
- 239000000839 emulsion Substances 0.000 claims description 127
- 230000002209 hydrophobic effect Effects 0.000 claims description 67
- 239000002086 nanomaterial Substances 0.000 claims description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 40
- 239000007788 liquid Substances 0.000 claims description 38
- 230000002535 lyotropic effect Effects 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 28
- 238000010008 shearing Methods 0.000 claims description 24
- 239000003381 stabilizer Substances 0.000 claims description 17
- 239000011550 stock solution Substances 0.000 claims description 11
- 241001012508 Carpiodes cyprinus Species 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- 239000013078 crystal Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 230000000699 topical effect Effects 0.000 claims description 7
- 235000010654 Melissa officinalis Nutrition 0.000 claims description 6
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 239000000865 liniment Substances 0.000 claims description 6
- 239000000693 micelle Substances 0.000 claims description 6
- 241000195940 Bryophyta Species 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- -1 diglycerides Chemical class 0.000 claims description 5
- 235000011929 mousse Nutrition 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000003599 detergent Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- CGIHFIDULQUVJG-UHFFFAOYSA-N phytantriol group Chemical group CC(C)CCCC(C)CCCC(C)CCCC(C)(O)C(O)CO CGIHFIDULQUVJG-UHFFFAOYSA-N 0.000 claims description 3
- 229920000223 polyglycerol Chemical class 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- 241000021559 Dicerandra Species 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 239000012071 phase Substances 0.000 description 170
- 239000003921 oil Substances 0.000 description 80
- 235000019198 oils Nutrition 0.000 description 68
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000009472 formulation Methods 0.000 description 12
- 239000004973 liquid crystal related substance Substances 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 8
- 235000019489 Almond oil Nutrition 0.000 description 7
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 7
- 239000008168 almond oil Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 6
- 238000000235 small-angle X-ray scattering Methods 0.000 description 6
- 238000001464 small-angle X-ray scattering data Methods 0.000 description 6
- 244000062730 Melissa officinalis Species 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000003906 humectant Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000001370 static light scattering Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 235000019486 Sunflower oil Nutrition 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000008524 evening primrose extract Nutrition 0.000 description 3
- 239000010475 evening primrose oil Substances 0.000 description 3
- 229940089020 evening primrose oil Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000010287 polarization Effects 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000002600 sunflower oil Substances 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Chemical class 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Chemical class 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 229940074096 monoolein Drugs 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- CGIHFIDULQUVJG-VNTMZGSJSA-N phytantriol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@@](C)(O)[C@H](O)CO CGIHFIDULQUVJG-VNTMZGSJSA-N 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000010677 tea tree oil Substances 0.000 description 2
- 229940111630 tea tree oil Drugs 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Chemical class 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Chemical class 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical class CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920002359 Tetronic® Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Chemical class 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000009956 central mechanism Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002018 neem oil Substances 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000008385 outer phase Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000010951 particle size reduction Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000120 polyethyl acrylate Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001454 recorded image Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006264 topical foam Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical group [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0295—Liquid crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/064—Water-in-oil emulsions, e.g. Water-in-silicone emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/068—Microemulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/21—Emulsions characterized by droplet sizes below 1 micron
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
- A61K2800/33—Free of surfactant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Colloid Chemistry (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Description
さらに望ましい実施形態では、当該エマルションの前記総含水率は、少なくとも70%(w/w)であり、特に75%(w/w)である。
さらに望ましい実施形態では、当該エマルションの前記親水性相は、ヒドロゲル化剤をさらに含む。
特定の実施形態において、その方法は、調製温度と、前記エマルションの総含水率と、前記エマルションの前記疎水性相において親水性親油性バランスの両親媒性分子における油に対する比率と、前記親水性相におけるヒドロゲル化剤の存在とからなる群から選択されるいずれか一つ又は複数の調製パラメータを調整することによって、前記疎水性相において形成される前記リオトロピック液晶性ナノ構造体の結晶相を制御することをさらに含む。
さらに望ましい実施形態では、当該方法における前記予混合する工程を少なくとも15,000rpmの回転速度、かつ少なくとも25,000s−1のせん断速度で行う。
図1の左のパネルにおいて、ナノ構造体を含む従来の水中油型分散系を示す。安定剤は、製剤を調製及び安定化するために必要である。その一方で、本発明に従う油中水型エマルションを調製する場合、水油相間用の乳化安定剤を必要とせず、分子安定剤及びコロイド安定剤のどちらも必要としない。正しくは、リオトロピック液晶性ナノ構造体の製剤及び所望の親水性相の高密度充填によって、製剤の安定性を実現する。
本発明は、水油相間用の乳化安定剤を使用せず、分子安定剤及びコロイド安定剤のどちらも使用することなく、高濃度で安定した油中水型エマルションを生成することができるという予期しない研究結果に基づく。この結果は、エマルションの連続疎水性相を形成するリオトロピック液晶性ナノ構造体の集合によって実現される。高温状態におけるせん断力の利用によって、本明細書において説明するエマルションを効率的に調製することができる。調製中に実験条件を制御することによって、目的の特定の利用に適した物理化学的特性を有する「カスタマイズ」したエマルションの調製が可能である。
説明及び請求項において「含む」という用語を用いる場合、他の構成要素又は工程は、除外されない。本発明の目的として、「からなる」という用語は、「含む」という用語の望ましい実施形態であると考慮される。本明細書の以降において、群が少なくとも一定数の実施形態を含むことを規定しており、望ましくは、これらの実施形態のみからなる群を開示するということも理解される。
に総説されている)。これらの種々の型のそれぞれは、分子秩序の異なる程度を有している。しかし、本発明における油中水型エマルションの連続疎水性相は、ラメラ相、すなわち両親媒性分子の層状構造又は積層構造を含まない。
特定の実施形態では、方法は、調製温度、エマルションの総含水率、エマルションの疎水性相において低い親水性親油性バランスの両親媒性分子における油に対する比率、及び親水性相におけるヒドロゲル化剤の存在からなる群から選択されるいずれか一つ又は複数の調製パラメータを調整することによって、疎水性相において形成されるリオトロピック液晶性ナノ構造体の結晶相を制御することをさらに含む。たとえばヘキサゴナル相を有するリオトロピック液晶性ナノ構造体といった所望のナノ構造体を有する油中水型エマルションを生成するために、特にこれらのパラメータのいずれか一つ又は複数を監視し、適用できる場合には、これに基づいて調整する。このように、調製パラメータを変更することによって、特定の利用に特に適合するような「カスタマイズ」又は「仕立て」たエマルションの調製が可能である。例示的な調製パラメータの結果として得られる各種のリオトロピック液晶性ナノ構造体を上記に説明している。
16gの「油相」(疎水性相)を約30℃で混合することにより調製する。この油相は、4.48gのグリセロールモノオレイン(GMO:glycerol monoolein)、6.72gのジグリセロールモノオレイン(DGMO:diglycerol monoolein)、4.67gのアーモンドオイル、及び0.13gのティーツリー油からなる。
11gの「油相」(疎水性相)を約30℃で混合することにより調製する。この油相は、3.08gのGMO、4.62gのDGMO、1.65gのアーモンドオイル、及び1.65gのひまわり油からなる。
160gの「油相」(疎水性相)を約30℃で混合することにより調製する。この油相は、44.8gのGMO、67.2gのDGMO、及び48gの月見草油からなる。
11gの「油相」(疎水性相)を約30℃で混合することにより調製する。この油相は、8.24gのMLO(DIMODAN(登録商標) U/J)、0.92gのアーモンドオイル、及び0.92gのR(+)−リモネンからなる。
15.2gの「油相」(疎水性相)を約40℃で混合することにより調製する。この油相は、12.0gのMLO(DIMODAN U/J)、2.13gのアーモンドオイル、及び1.07gのオレイン酸からなる。
15.2gの「油相」(疎水性相)を約40℃で混合することにより調製する。この油相は、12.0gのMLO(DIMODAN U/J)、2.13gのアーモンドオイル、及び1.07gのオレイン酸からなる。
Claims (13)
- 親水性相が分散した連続疎水性相を含む油中水型エマルションであって、
(1)当該エマルションは、30%〜95%(w/w)の範囲の総含水率を有し、
(2)当該エマルションは、界面活性剤および洗剤からなる群から選択される乳化安定剤を含まず、
(3)前記連続疎水性相における低い親水性親油性バランスの両親媒性分子の油との比率は、前記低い親水性親油性バランスの両親媒性分子が50%〜96%(w/w)の範囲であり、
(4)前記連続疎水性相は、5%〜40%(w/w)の水を含むリオトロピック液晶性ナノ構造体で形成され、かつ、ラメラ相を含まず、
前記低い親水性親油性バランスの両親媒性分子は、モノグリセリド、ジグリセリド、トリグリセリド、ポリグリセロールエステル、フィタントリオール、脂肪酸、及びリン脂質からなる群から選択されるとともに、その親水性親油性バランス値が4及び11の間の範囲であり、
前記リオトロピック液晶性ナノ構造体は、ヘキサゴナル、及び離散ミセルキュービックからなる群から選択される結晶相を有する油中水型エマルション。 - 前記親水性相が、0.1μm〜50μmの範囲の直径を有する液滴の形で分散した請求項1に記載の油中水型エマルション。
- 前記総含水率は、少なくとも70%(w/w)である請求項1又は請求項2に記載の油中水型エマルション。
- 前記総含水率は、少なくとも75%(w/w)である請求項3に記載の油中水型エマルション。
- 前記油は、天然油である請求項1〜請求項4のいずれか一項に記載の油中水型エマルション。
- 前記親水性相は、ヒドロゲル形成剤をさらに含む請求項1〜請求項5のいずれか一項に
記載の油中水型エマルション。 - 請求項1〜請求項6のいずれか一項に記載のリオトロピック液晶性ナノ構造体で形成される連続疎水性相を含む油中水型エマルションの調製方法であって、
(a)少なくとも4,000rpmの回転速度かつ少なくとも40℃で親水性相及び疎水性相の二つの流体を予混合することによって、エマルション原液を生成することと、
(b)前記エマルション原液をせん断装置に配置することと、
(c)少なくとも4,500s−1のせん断速度で作動させ、得られた最終エマルションを周囲温度まで冷却することによって、リオトロピック液晶性ナノ構造体で形成されるエマルションの連続疎水性相を生成することと
を含む方法。 - 前記せん断装置は、クエット層流せん断装置である請求項7に記載の方法。
- 調製温度と、前記エマルションの総含水率と、前記エマルションの前記疎水性相における低い親水性親油性バランスの両親媒性分子の油との比率と、前記親水性相におけるヒドロゲル形成剤の存在とからなる群から選択されるいずれか一つ又は複数の調製パラメータを調整することによって、前記疎水性相において形成される前記リオトロピック液晶性ナノ構造体の結晶相を制御することをさらに含む請求項7又は請求項8に記載の方法。
- 前記予混合する工程を少なくとも60℃で行う請求項7〜請求項9のいずれか一項に記載の方法。
- 前記予混合する工程を少なくとも15,000rpmの回転速度で行い、
少なくとも25,000s−1のせん断速度が適用される、請求項7〜請求項10のいずれか一項に記載の方法。 - 化粧品組成物又は医薬品組成物の調製用の請求項1〜請求項6のいずれか一項に記載の油中水型エマルションの使用方法であって、前記組成物は、一つ又は複数の有効成分を含む油中水型エマルションの使用方法。
- 前記化粧品組成物又は前記医薬品組成物は、局所使用用であり、特に、クリーム剤、ローション剤、ムース剤、及びバーム剤からなる群から選択される請求項12に記載の使用方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11193358.6A EP2604253A1 (en) | 2011-12-13 | 2011-12-13 | Water-in-oil emulsions and methods for their preparation |
EP11193358.6 | 2011-12-13 | ||
PCT/EP2012/075448 WO2013087791A1 (en) | 2011-12-13 | 2012-12-13 | Water-in-oil emulsions and methods for their preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014532051A JP2014532051A (ja) | 2014-12-04 |
JP5952410B2 true JP5952410B2 (ja) | 2016-07-13 |
Family
ID=47458928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014532439A Expired - Fee Related JP5952410B2 (ja) | 2011-12-13 | 2012-12-13 | 油中水型エマルション及びその調製方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20140294904A1 (ja) |
EP (2) | EP2604253A1 (ja) |
JP (1) | JP5952410B2 (ja) |
CA (1) | CA2850599C (ja) |
WO (1) | WO2013087791A1 (ja) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CA2821992A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3492109B1 (en) | 2011-10-03 | 2020-03-04 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
JP2015501844A (ja) | 2011-12-16 | 2015-01-19 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物 |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
EP2833923A4 (en) | 2012-04-02 | 2016-02-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
LT2922554T (lt) | 2012-11-26 | 2022-06-27 | Modernatx, Inc. | Terminaliai modifikuota rnr |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
ES2836772T3 (es) | 2014-04-30 | 2021-06-28 | Fujifilm Corp | Composición liposomal y método para producirla |
US10722462B2 (en) | 2014-12-10 | 2020-07-28 | Council Of Scientific And Industrial Research | Discontinuous reverse micellar composition in cubic FD3M phase for sustained release of therapeutic drugs |
HUE057613T2 (hu) | 2015-09-17 | 2022-05-28 | Modernatx Inc | Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására |
KR102084340B1 (ko) | 2015-11-02 | 2020-03-03 | 후지필름 가부시키가이샤 | 젬시타빈 리포솜 조성물을 포함하는 종양 치료제 및 키트 |
DK3394030T3 (da) | 2015-12-22 | 2022-03-28 | Modernatx Inc | Forbindelser og sammensætninger til intracellulær afgivelse af midler |
EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
CA3056133A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
US11969506B2 (en) | 2017-03-15 | 2024-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
FI3596041T3 (fi) | 2017-03-15 | 2023-01-31 | Yhdiste ja koostumuksia terapeuttisten aineiden antamiseen solun sisään | |
WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
EP3852728B1 (en) | 2018-09-20 | 2024-09-18 | ModernaTX, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
CN109363993A (zh) * | 2018-11-29 | 2019-02-22 | 四川省中医药科学院 | 一种一步均质乳化冷却成型方法及其应用 |
US11066355B2 (en) | 2019-09-19 | 2021-07-20 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
JP2021059680A (ja) * | 2019-10-08 | 2021-04-15 | 花王株式会社 | 液晶組成物 |
JP7242578B2 (ja) * | 2020-01-08 | 2023-03-20 | 旭化成ワッカーシリコーン株式会社 | 液晶乳化方法および液晶乳化物 |
JP7565159B2 (ja) * | 2020-02-28 | 2024-10-10 | 花王株式会社 | 口腔用組成物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4767625A (en) * | 1985-09-02 | 1988-08-30 | Kao Corporation | Lamella type single phase liquid crystal composition and oil-base cosmetic compositions using the same |
GB9312100D0 (en) * | 1993-06-11 | 1993-07-28 | Procter & Gamble | Cosmetic make-up compositions |
FR2747321B1 (fr) * | 1996-04-16 | 1998-07-10 | Centre Nat Rech Scient | Procede de preparation d'une emulsion |
US20020094341A1 (en) * | 1998-11-03 | 2002-07-18 | Lise W. Jorgensen | Skin moisturizer compositions containing a sebum control agent |
US7846903B2 (en) * | 2004-10-19 | 2010-12-07 | National Institute Of Advanced Industrial Science And Technology | Type II cubic liquid crystal composition |
JP4817435B2 (ja) * | 2006-04-26 | 2011-11-16 | 株式会社コスモステクニカルセンター | 皮膚外用剤 |
JP4629799B2 (ja) * | 2009-03-27 | 2011-02-09 | 株式会社資生堂 | 油中水型乳化組成物 |
FR2948024B1 (fr) * | 2009-07-17 | 2020-01-10 | Centre National De La Recherche Scientifique - Cnrs - | Emulsion activable par ultrasons et son procede de fabrication. |
JP4834775B2 (ja) * | 2010-03-04 | 2011-12-14 | 株式会社 資生堂 | 日焼け止め用組成物 |
JP2012017318A (ja) * | 2010-06-07 | 2012-01-26 | Nikko Chemical Co Ltd | 液晶及びそれを含有する皮膚外用剤 |
-
2011
- 2011-12-13 EP EP11193358.6A patent/EP2604253A1/en not_active Withdrawn
-
2012
- 2012-12-13 WO PCT/EP2012/075448 patent/WO2013087791A1/en active Application Filing
- 2012-12-13 US US14/349,241 patent/US20140294904A1/en not_active Abandoned
- 2012-12-13 JP JP2014532439A patent/JP5952410B2/ja not_active Expired - Fee Related
- 2012-12-13 EP EP12808339.1A patent/EP2790655B1/en active Active
- 2012-12-13 CA CA2850599A patent/CA2850599C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2790655B1 (en) | 2016-11-09 |
EP2604253A1 (en) | 2013-06-19 |
WO2013087791A1 (en) | 2013-06-20 |
JP2014532051A (ja) | 2014-12-04 |
CA2850599C (en) | 2016-12-06 |
US20140294904A1 (en) | 2014-10-02 |
CA2850599A1 (en) | 2013-06-20 |
EP2790655A1 (en) | 2014-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5952410B2 (ja) | 油中水型エマルション及びその調製方法 | |
Roland et al. | Systematic characterization of oil-in-water emulsions for formulation design | |
Djordjevic et al. | In vitro release of diclofenac diethylamine from caprylocaproyl macrogolglycerides based microemulsions | |
Dhawan et al. | Enhanced transdermal permeability of piroxicam through novel nanoemulgel formulation | |
Tadros | Future developments in cosmetic formulations | |
RU2397754C2 (ru) | Эмульсия масло-в-воде как средство для доставки | |
Valldeperas et al. | Sponge phases and nanoparticle dispersions in aqueous mixtures of mono-and diglycerides | |
Guillot et al. | Influence of the stabilizer concentration on the internal liquid crystalline order and the size of oil-loaded monolinolein-based dispersions | |
Shrestha et al. | Phase behavior of diglycerol fatty acid esters− nonpolar oil systems | |
Klang et al. | Semi-solid sucrose stearate-based emulsions as dermal drug delivery systems | |
Nilsson et al. | Characterization of oil-free and oil-loaded liquid-crystalline particles stabilized by negatively charged stabilizer citrem | |
JP2012214409A (ja) | W/o/w型複合エマルション | |
Chemelli et al. | Amino acid induced modification of self-assembled monoglyceride-based nanostructures | |
Hashizaki et al. | A novel reverse worm-like micelle from a lecithin/sucrose fatty acid ester/oil system | |
Macierzanka et al. | Effect of crystalline emulsifier composition on structural transformations of water-in-oil emulsions: Emulsification and quiescent conditions | |
Salim et al. | Swelling of bicontinuous cubic phases in Guerbet glycolipid: Effects of additives | |
Percebom et al. | Phase behavior controlled by the addition of long-chain n-alcohols in systems of cationic surfactant/anionic polyion complex salts and water | |
Hashizaki et al. | Highly viscoelastic reverse worm-like micelles formed in a lecithin/urea/oil system | |
JP6959596B2 (ja) | 皮膚外用剤および皮膚バリア機能改善剤 | |
Kulkarni et al. | Water-in-oil nanostructured emulsions: towards the structural hierarchy of liquid crystalline materials | |
Mouri et al. | Development of pharmaceutical clear gel based on Peceol®, lecithin, ethanol and water: Physicochemical characterization and stability study | |
Junginger | Ointments and creams as colloidal drug delivery systems | |
Lim et al. | Formation of liquid crystal/gel emulsions to nano-emulsions constructed by polyalkoxylated fatty alcohol (PAFA)-based mixed surfactant systems | |
Khodakiya et al. | Microemulsions as enhanced drug delivery carrier: an overview | |
Godoy et al. | Microstructural and Viscoelastic Properties of Liquid Crystal Phases of Soybean Lecithin with Olive and Castor Oils at Low Water Contents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150312 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150317 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150617 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160316 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160531 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160609 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5952410 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |